259 related articles for article (PubMed ID: 27392814)
1. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
Kim JH; Benefield RJ; Ditolla K
Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
5. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
7. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
10. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
11. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole salvage treatment for invasive fungal infection.
Kim JH; Williams K
Mycopathologia; 2014 Oct; 178(3-4):259-65. PubMed ID: 25103141
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
Welch S; Pallotta A; Weber C; Siebenaller C; Cober E; Neuner E
Mycoses; 2017 Apr; 60(4):241-243. PubMed ID: 27910211
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole salvage therapy: The Posifi study.
Fortun J; Gioia F; Cardozo C; Gudiol C; Diago E; José Castón J; Muñoz P; López J; Puerta-Alcalde P; Enzenhofer M; Ramos A; Frutos A; Machado M; Garcia-Vidal C; Parody R; Martín-Dávila P
Mycoses; 2019 Jun; 62(6):526-533. PubMed ID: 30864238
[TBL] [Abstract][Full Text] [Related]
16. [Use of posaconazole in children: Experience in a tertiary pediatric hospital].
Rosanova MT; Voto C; Mussini MS; Sarkis C; Gómez S; Sberna N; Carnovale S; Caracciolo B; Lede R
Arch Argent Pediatr; 2018 Jun; 116(3):e451-e454. PubMed ID: 29756722
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.
Huang X; Wang F; Chen Y; Liu T; Wang J; Hu J; Jie J; Chen F; Wang S; Shen Z; Yu L; Yu K; Liang Y
Future Microbiol; 2012 Feb; 7(2):201-9. PubMed ID: 22324990
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
[TBL] [Abstract][Full Text] [Related]
19. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
Van Daele R; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
